SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

__________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  March 20, 2014

THE FEMALE HEALTH COMPANY 
(Exact name of registrant as specified in its charter)

Wisconsin
(State or other jurisdiction of incorporation)

1-13602
  
39-1144397
(Commission File Number)
  
(I.R.S. Employer I.D. Number)

515 North State Street
Suite 2225
Chicago, Illinois
  
 
 
60654
(Address of Principal Executive Offices)
  
(Zip Code)

312-595-9123
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR230.425)
     
 o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
 o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
 o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
           

 
 
 
 


Section 5 – Corporate Governance and Management

Item 5.07   Submission of Matters to a Vote of Security Holders

The Annual Meeting of Shareholders of The Female Health Company (the "Company") was held on March 20, 2014.  A total of 28,830,502 shares of common stock were eligible to vote at the Annual Meeting.  The matters voted on at the Annual Meeting were as follows:

1.   Election of Directors:

The following individuals were nominated for election to the Board of Directors for terms that expire at the next annual meeting of shareholders.  All of the nominated directors were elected.  The results of the vote on the election of directors were as follows:

 
Name
  
Votes
      For      
  
Votes
    Withheld    
  
Broker
   Non-Votes   
David R. Bethune
  
17,932,735
  
721,772
  
7,610,652
Stephen M. Dearholt
  
18,163,774
  
490,733
  
7,610,652
Donna Felch
  
18,041,106
  
613,401
  
7,610,652
Mary Margaret Frank, Ph.D.
  
18,176,995
  
477,512
  
7,610,652
William R. Gargiulo, Jr.
  
18,257,131
  
397,376
  
7,610,652
Karen King
  
18,370,025
  
284,482
  
7,610,652
Andrew S. Love
  
18,236,364
  
418,143
  
7,610,652
O.B. Parrish
  
18,271,836
  
382,671
  
7,610,652
Richard E. Wenninger
  
18,165,352
  
489,155
  
7,610,652

2.   Ratification of Auditors:

The shareholders voted to ratify the appointment by the Company's Audit Committee of McGladrey LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2014.

    Votes For    
  
  Votes Against
  
    Abstentions  
  
   Broker Non-Votes  
26,054,936
  
173,179
  
37,044
  
–


                                                                 
 
2
 

3.   Advisory (non-binding) vote on the executive compensation of the Company's named executive officers:

The shareholders voted in favor of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting of Shareholders.

   Votes For    
  
  Votes Against 
  
    Abstentions   
  
   Broker Non-Votes 
14,914,936
  
3,090,503
  
649,068
  
7,610,652


                                                              
 
3
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE FEMALE HEALTH COMPANY
Date:  March 25, 2014
BY  Michele Greco                                                                  
       Michele Greco, Vice President
         and Chief Financial Officer

4